Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension

BACKGROUND: Evaluate the impact of sex on tofacitinib efficacy, safety and persistence (time to discontinuation) in patients with psoriatic arthritis (PsA). METHODS: Data were pooled from two phase 3 randomised controlled trials. Patients were randomised to tofacitinib 5 mg or 10 mg two times per da...

Descripción completa

Detalles Bibliográficos
Autores principales: Eder, Lihi, Gladman, Dafna D, Mease, Philip, Pollock, Remy A, Luna, Rayana, Aydin, Sibel Z, Ogdie, Alexis, Polachek, Ari, Gruben, David, Cadatal, Mary Jane, Kinch, Cassandra, Strand, Vibeke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030648/
https://www.ncbi.nlm.nih.gov/pubmed/36958766
http://dx.doi.org/10.1136/rmdopen-2022-002718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030648/
https://www.ncbi.nlm.nih.gov/pubmed/36958766
http://dx.doi.org/10.1136/rmdopen-2022-002718

Ejemplares similares